Review Article
The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma
Table 5
Salvage therapy in relapsing/refractory DLBCLs previously exposed to rituximab.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*The choice of conditioning regimen depended on the patient’s age, the extent of previous therapy, and the clinical trials active at the time of transplantation (see [40, 41]). WHO: World Health Organization classification of NHL; R: rituximab; ESHAP: etoposide, methylprednisolone, cisplatin, and cytarabine; CT: multiple variable regimes; ICE: ifosfamide, carboplatin, and etoposide; DHAP: cisplatin, cytarabine, and dexamethasone; BEAM: carmustine, etoposide, cytarabine, and melphalan; N.S.: not significant. |